News and Announcements
Innate Immuno’s MS Trial Drug Gets Global Spotlight
- Published October 12, 2012 9:38PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Auckland, NZ, October 12 2012: Research details of a drug that may help people with secondary progressive multiple sclerosis (MS), developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, is being highlighted at the worlds biggest annual gathering of MS specialists and pharmaceutical companies, ECTRIMS, in Lyon, France today.
Innates study co-principal investigator, Dr Alison Luckey, will talk about the result of 1B/2A trials of its drug MIS416 in the late breaking news section of ECTRIMS. More than 6,000 people attend the conference.
——-
To view the full article, please click here.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
